<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00595257</url>
  </required_header>
  <id_info>
    <org_study_id>TriCell/CT/IND-001</org_study_id>
    <nct_id>NCT00595257</nct_id>
  </id_info>
  <brief_title>Feasability Study of Autologous Bone Marrow Aspirate Concentrate for Treatment of CLI</brief_title>
  <official_title>Feasibility Study of the Safety and Activity of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the Treatment of Non Reconstructable Critical Limb Ischemia Due to Peripheral Arterial Occlusive Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harvest Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harvest Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if concentrated nucleated cells from your own bone&#xD;
      marrow, injected or infused into an ischemic limb, will restore sufficient blood flow to&#xD;
      avoid amputation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>avoid amputation</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>measurement of hemodynamic response</measure>
    <time_frame>60 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Arterial Occlusive Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection of BMAC into ischemic limb</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection and Infusion of BMAC into ischemic lower limb</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>centrifuge, laboratory, tabletop (SmartPReP2 BMAC System)</intervention_name>
    <description>autologous bone marrow aspirate will be concentrated using the SmartPRep2 BMAC system and then injected/infused into ischemic limbs</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>SmartPReP2 BMAC System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of Critical Limb Ischemia per protocol (see diagnostic criteria #2) with&#xD;
             regard to the study limb.&#xD;
&#xD;
             Existence of a PAOD with clinical presentation corresponding to Rutherford Category 4&#xD;
             or Category 5 as defined in the reporting standards adopted by the Society of Vascular&#xD;
             Surgeons (table 1)&#xD;
&#xD;
          2. Patient meets at least one of the following diagnostic criteria in the study limb:&#xD;
&#xD;
               -  Ankle artery occlusion pressure absolute &lt;50 mmHg or ABI &lt;0.4&#xD;
&#xD;
               -  Toe artery occlusive pressure &lt; 40mm Hg or TBI (&lt;0.4)&#xD;
&#xD;
               -  TcPO2 &lt;20 mmHg lying down breathing room air, if available.&#xD;
&#xD;
          3. There is no reasonable open surgical or endovascular revascularization option as&#xD;
             determined by the treating vascular specialist. Factors that may contribute to the&#xD;
             determination of inoperability may include:&#xD;
&#xD;
               -  Anatomical considerations&#xD;
&#xD;
                    -  No outflow targets&#xD;
&#xD;
                    -  No appropriate conduit (i.e. vein for bypass)&#xD;
&#xD;
                    -  Long segment occlusions or calcified lesions that predict poor outcome with&#xD;
                       endovascular approaches.&#xD;
&#xD;
               -  High risk medical conditions&#xD;
&#xD;
                    -  Unstable cardiac disease.&#xD;
&#xD;
                    -  Renal insufficiency&#xD;
&#xD;
               -  History of prior failed revascularization attempts&#xD;
&#xD;
               -  The patient's unsuitability must be confirmed by 2 qualified physicians.&#xD;
&#xD;
                    -  The attending vascular surgeon will provide the primary assessment.&#xD;
&#xD;
                    -  The confirmatory opinion must come from a fully licensed physician. (not a&#xD;
                       resident)&#xD;
&#xD;
                    -  If anatomical considerations are invoked, the second physician may be a&#xD;
                       vascular surgeon, interventional radiologist, cardiologist, or vascular&#xD;
                       medicine specialist.&#xD;
&#xD;
                    -  If medical co-morbidity is deemed the high risk aspect, then the&#xD;
                       confirmatory opinion may be obtained from an internist, family physician,&#xD;
                       cardiologist, vascular medicine, nephrologists, or vascular surgeon.&#xD;
&#xD;
          4. Age &gt;18 years and ability to understand the planned treatment&#xD;
&#xD;
          5. Subject has read and signed the IRB/IEC approved Informed Consent form&#xD;
&#xD;
          6. Patients for whom the following medication(s) is prescribed must have a one month&#xD;
             stable baseline of appropriate/maximally tolerated therapy prior to enrollment:&#xD;
             Plavix/asprin therapy, anticoagulation therapy, cholesterol lowering agent, and or&#xD;
             blood pressure medication&#xD;
&#xD;
          7. Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000, INR ≤&#xD;
             1.6 unless on Coumadin, or PTT &lt;1.5 x control (to avoid bleeding complications)&#xD;
             Patients on Coumadin will be corrected prior to the procedure and must have an INR&lt;1.6&#xD;
             at the time of randomization/surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Life expectancy &lt;6 months due to concomitant illnesses&#xD;
&#xD;
          2. History of bone marrow diseases (especially NHL, MDS) that prohibit transplantation&#xD;
&#xD;
          3. Terminal renal failure with existing dependence on dialysis&#xD;
&#xD;
          4. Known active malignancy or results outside of normal limits from the following tests:&#xD;
             PAP, Chest X-ray, PSA, Mammogram, Hemocult unless follow-up studies reveal patient to&#xD;
             be cancer free..&#xD;
&#xD;
          5. Poorly controlled diabetes mellitus (HgbA1C&gt;10%)&#xD;
&#xD;
          6. Medical risk that precludes anesthesia (conscious sedation), or ASA Class 5&#xD;
&#xD;
          7. Life-threatening complications of the ischemia necessitating immediate amputation&#xD;
&#xD;
          8. Uncorrected iliac artery occlusion on index side&#xD;
&#xD;
          9. Extensive necrosis of the index limb or other conditions that make amputation&#xD;
             inevitable (Rutherford Category 6)&#xD;
&#xD;
         10. Active clinical infection being treated by antibiotics within one week of enrollment&#xD;
&#xD;
         11. Treatment with immunosuppressant drugs (including Prednisone &gt; 5 mg per day).&#xD;
&#xD;
         12. Female who is pregnant or nursing, or of child bearing potential and is not using a&#xD;
             reliable birth control method.&#xD;
&#xD;
         13. Underwent a major cardiovascular surgical procedure (carotid endarterectomy, open&#xD;
             arterial aneurysm or bypass surgery, or coronary artery bypass surgery) or an adverse&#xD;
             cardiovascular event (stroke or MI) within the 30 days prior to randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R E Arasan, MD</last_name>
    <role>Study Director</role>
    <affiliation>LifeCell India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sri Ramachandra University Medical Center</name>
      <address>
        <city>Porur</city>
        <state>Chennai</state>
        <zip>600 116</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>January 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2008</study_first_posted>
  <last_update_submitted>March 8, 2012</last_update_submitted>
  <last_update_submitted_qc>March 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAD, CLI, Critical Limb Ischemia, bone marrow, stem cell, injection, infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

